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Malmo¨ University Hospital,
Lund University, Malmo¨, SwedenThe most characteristic feature of eosinophils is their
content of highly cationic proteins, stored in cytoplasmic
granules. The main components of these so-called specific
granules are major basic protein (MBP), eosinophil
peroxidase (EPO), eosinophil-derived neurotoxin/eosino-
phil protein X (EDN/EPX) and eosinophil cationic protein
(ECP). The mechanisms involved in their release and their
functions in microbe-containing phagosomes or in the
extracellular environment may hold keys to many hitherto
unanswered questions relating to the roles of eosinophils in
host defense and inflammation.
Eosinophils were long considered mainly secretory cells,
releasing their granule content onto the surfaces of multi-
cellular parasites or into the extracellular environment.
However, they are also, especially after activation, capable
of phagocytosing bacteria, and can release their granule
contents into phagosomes where they can exert cytotoxic
effects [Fig. 1(A)]. In experimental models for the study of
binding and phagocytosis by eosinophils, serum-treated
zymosan (STZ) can be used. The binding of STZ to
eosinophils is mainly dependent on a receptor belonging to
the b2-integrin family of adhesion molecules, namely
complement receptor 3 (CR3, also called CD11b/CD18 or
Mac-1) (1). Eosinophil binding of STZ increases after
pretreatment (priming) with several agents, among them
platelet-activating factor (PAF), interleukin-3 (IL-3), IL-5,
granulocyte/macrophage-colony stimulating factor (GM-
CSF) (1), and tumour necrosis factor (TNF)-a (2). This
priming process increases the anity of CR3 for its ligand
(iC3b) on the particles.
Quantitative evaluation of eosinophil degranulation is
easiest to perform in assays where non-phagocytosable
surfaces are a target for release and granule contents can be
measured in the surrounding medium. Using such an assay
we have shown that activation of protein kinase C by PMA
induces ECP release in eosinophils adherent to a surface.
This release is dependent on signalling by b2-integrins (3).
Platelet-activating factor and GM-CSF also induce degra-
nulation shown to be dependent on a b2-integrin, i.e. CR3
(4). In addition, immobilized immunoglobulin induces
eosinophil degranulation that involves cooperative signal-
ling by CR3 (5).
We have used serum-opsonized Sephadex (SOS), which
represents a semi-physiological parasite model, to investi-
gate release of ECP from eosinophils [Fig. 1(B)]. The
release in this system is also mainly dependent on binding
and signalling through CR3 (2). Priming of eosinophils
with IL-5 or TNF-a increases ECP release in response to
Fig. 1. (a) Electron micrograph showing release of granule
protein (EPO) into a phagosome containing serum-treated
zymosan (STZ). EPO is detected by a specific antibody
visualized by colloidal gold. Specific granules (g) fusing
and emptying their content into the phagosome. Nucleus
(n). (Courtesy of Dr Jero Calafat, The Netherlands
Cancer Institute, Amsterdam). (b) A semiphysiologic
parasite model where an eosinophil (arrow) tries to
phagocytose a large serum-opsonized Sephadex bead (S)
(‘frustrated phagocytosis’). During this process, granule
proteins are being released into the surrounding medium.
(Adapted from ref. 2.)
Fig. 2. Eosinophil degranulation in response to serum-
opsonized Sephadex (SOS), detected as ECP release into
the surrounding medium. C5a and PAF both enhance
ECP release in response to SOS, while on their own they
induce little or no release in this system. (Adapted from
ref. 6.)
ABSTRACTS 1257SOS, while these substances on their own cause little or no
degranulation. PAF has been reported to induce degranu-
lation in eosinophils. However, we found that both PAF
and the complement fragment C5a enhance eosinophil
degranulation in response to SOS rather than acting as
secretagogues themselves (Fig. 2) (6). The experiments
using serum-opsonized particles suggest that eosinophil
binding parallels degranulation in these systems.
Eosinophils are potent producers of PAF and autocrine/
paracrine effects of this substance have been reported to be
important for the enhancement of eosinophil function upon
encounter with serum-opsonized particles (7). However, the
PAF receptor antagonist WEB 2086 had no effect on ECPrelease in response to SOS in our system, while inhibition of
phospholipase A2 reduced ECP release (2).
The mechanisms underlying the increase in anity of
CR3 for its ligand(s) on serum-opsonized particles are
unclear. However, it was recently shown that phospholipase
D-derived phosphatidic acid is involved (8), while activa-
tion of protein kinase C gave no change in anity but
caused upregulation of CR3 on the cell surface.
The strongest signals for eosinophil degranulation in
these experimental models seem to be immobilized im-
munoglobulins and/or complement fragments, while solu-
ble stimuli have only weak stimulatory effects on
degranulation, or rather, act as enhancers of degranulation.
The in vivo situation at an inflammatory site presents a
more complicated context, with complex surfaces and an
array of different cytokines. There may also be other
secretory compartments in eosinophils that are subject to
different regulatory mechanisms, for example compartments
1258 ABSTRACTSholding newly synthesized proteins (e.g. cytokines) that are
released constitutively or after specific stimuli.
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1999; 340: 95–101.Fig. 1. In situ detection of apoptotic eosinophils in nasal
polyp tissues. (a) Fragmented DNA in apoptotic cells was
detected by the TUNEL technique. Eosinophils were
identified by peroxidase staining. (b) Apoptotic cells were
detected by Annexin V binding. Sections were
counterstained with haematoxylin. Original
magnification: 6 400. The figure demonstrates the
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Apoptosis is the most common form of physiological cell
death, which is necessary to maintain correct cell numbers.
This is also true for inflammatory cells such as eosinophils
that are constantly generated in the bone marrow and die
via apoptosis (Fig. 1). Apoptosis is characterized by
morphological changes in the dying cell. The most readily
observed morphological features involve the nucleus, where
the chromatin becomes extremely condensed before a
complete collapse of the nucleus can be observed [for
eosinophils, these changes are reviewed in (1)]. Moreover, a
specific form of DNA fragmentation is another important
hallmark of apoptotic cells. There are many different
techniques to analyse DNA fragmentation. To detect
apoptosis in tissues, the terminal deoxynucleotidyl Trans-
ferase (TdT) Uridine triphosphate (UTP) Nick End
Labelling (TUNEL) method is frequently used. Another
possibility is to measure the redistribution of phosphati-
dylserine (PS) in apoptotic cells by Annexin V binding
(Fig. 1).*Work in the author’s laboratory is supported by the Swiss
National Science Foundation (grant No. 32-49210.96), the Saurer
Foundation, Zurich, the OPO Foundation, Zurich, the Foundation
for Scientific Research, Zurich, and the EMDO Foundation,
Zurich.There is increasing evidence for a pivotal role of T cells in
various diseases associated with eosinophilia such as
allergic and asthmatic diseases (2) as well as in a subgroup
of idiopathic eosinophilia (3,4). In these diseases, T cells
produce large amounts of interleukin-5, which limits
eosinophil apoptosis (5). This mechanism serves to selec-
tively amplify eosinophil accumulation (6). Overproduction
of survival factors and delayed apoptosis is not unique for
eosinophilic diseases since it can also be observed in
neutrophilic inflammation (7).
Eosinophils do not only undergo apoptosis in the
absence of survival factors. They also express at least one
functional death receptor, the Fas receptor (CD95, APO-1)
(8,9). Nitric oxide, in contrast to eosinophil haematopoie-
tins, prevents Fas receptor-mediated apoptosis in eosino-
phils (10). Thus, nitric oxide, a secretory product released in
increased amounts within chronic inflammatory responses,
might be important in determining whether an eosinophil
survives or undergoes apoptosis of eosinophils upon Fas
